Bened’s R&D Manager Wins One of Taiwan’s Highest Honors in Technology: The 2025 Pan Wen-Yuan Young Researcher Innovation Award

July 29th, 2025 | Tuesday

Bened Biomedical is proud to announce that its R&D Manager, Dr. Fu-Sheng Deng, has received the 2025 Young Researcher Innovation Award from the Pan Wen-Yuan Foundation — one of the most prestigious recognitions in Taiwan’s science and technology community. Often likened to the Nobel Prize in Taiwan’s tech sector, this award honors outstanding young researchers and entrepreneurs making significant contributions in fields such as electronics, information technology, communications, and biotechnology.

Among only three recipients nationwide this year, Dr. Deng was selected for his groundbreaking work in psychobiotic and postbiotic innovation, and his leadership in advancing microbiome-based applications with global impact.

Pioneering Innovation in Psychobiotics and Microbial Science

Since joining Bened Biomedical in 2022, Dr. Deng has played a pivotal role in expanding the company’s research in psychobiotics — beneficial microbes that interact with the gut-brain axis — and their postbiotic derivatives. With a deep academic background in microbiology and applied life sciences, he has led the development of multiple novel bacterial strains with neuroactive potential, contributing to Bened’s growing portfolio of scientifically validated and globally patented products.

His work includes:

PS150: Identified for its heat-stable exopolysaccharides (EPS), which remain biologically active even after sterilization. This discovery has opened new possibilities in postbiotic applications beyond the limitations of live probiotics.

PS128: Bened’s flagship strain studied for its interaction with neurotransmitter pathways, which has been widely recognized in the international psychobiotic community.

PS133: A promising new-generation strain investigated for its potential role in gut-brain axis modulation and multi-pathway health support.

All strains developed under Dr. Deng’s leadership are optimized for stability, safety, and formulation versatility — ideal for capsules, powders, and functional foods — and are protected by global intellectual property portfolios.

From Research to Real-World Impact: Scaling Microbial Innovation Globally

To date, Bened Biomedical has completed over 27 clinical and preclinical studies, secured 93 international patents, and published more than 50 peer-reviewed articles in fields spanning neuroscience, microbiome interaction, and functional biochemistry. Its innovations have received global recognition from institutions including Future Market Insights and Stratagem Market Insights, which named PS128 one of the world’s leading psychobiotic technologies.

These achievements underscore Bened’s commitment to translating rigorous research into real-world health applications.

A Mission-Driven Company Elevating Taiwan's Global Scientific Standing

Bened Biomedical was founded by Professor Ying-Chieh Tsai of National Yang Ming Chiao Tung University, one of Asia’s foremost probiotic researchers. The company is rooted in a clear mission: Honor God; Serve the World. Today, Bened is one of the few biotechnology firms globally focused on psychobiotic and postbiotic innovation for mental and neurological health.

Headquartered in Taipei with offices in San Francisco and Shanghai, Bened’s brands — including Neuralli™ and InSeed® — are now distributed in over 60 countries, bringing Taiwan-developed microbiome technology to a worldwide audience.

Dr. Deng’s recognition by the Pan Wen-Yuan Foundation is both a personal achievement and a reflection of Bened Biomedical’s long-standing commitment to scientific excellence, innovation, and global impact.